Oragenics, Inc. (OGEN)
0.201
-0.15
(-42.59%)
USD |
NYAM |
Nov 13, 16:00
0.2061
+0.01
(+2.54%)
After-Hours: 19:59
Oragenics Enterprise Value : -0.9239M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | -0.9239M |
| November 12, 2026 | -0.2511M |
| November 11, 2026 | -0.2918M |
| November 10, 2026 | -0.2827M |
| November 09, 2026 | -0.2299M |
| November 06, 2026 | -0.2554M |
| November 05, 2026 | -0.2561M |
| November 04, 2026 | -0.1523M |
| November 03, 2026 | -0.1609M |
| November 02, 2026 | -0.1605M |
| October 30, 2026 | -0.1433M |
| October 29, 2026 | -0.1424M |
| October 28, 2026 | -0.1162M |
| October 27, 2026 | -0.1794M |
| October 26, 2026 | -0.0328M |
| October 23, 2026 | 0.0509M |
| October 22, 2026 | -0.0021M |
| October 21, 2026 | 0.0318M |
| October 20, 2026 | 0.1274M |
| October 19, 2026 | 0.0733M |
| October 16, 2026 | 0.1315M |
| October 15, 2026 | 0.1364M |
| October 14, 2026 | 0.1409M |
| October 13, 2026 | 0.1856M |
| October 12, 2026 | 0.1888M |
| Date | Value |
|---|---|
| October 09, 2026 | 0.2267M |
| October 08, 2026 | 0.2583M |
| October 07, 2026 | 0.4247M |
| October 06, 2026 | 0.3575M |
| October 05, 2026 | 0.3625M |
| October 02, 2026 | 0.369M |
| October 01, 2026 | 0.335M |
| September 30, 2026 | 0.3882M |
| September 29, 2026 | -1.698M |
| September 28, 2026 | -1.736M |
| September 25, 2026 | -1.663M |
| September 24, 2026 | -1.595M |
| September 23, 2026 | -1.671M |
| September 22, 2026 | -1.518M |
| September 21, 2026 | -1.522M |
| September 18, 2026 | -1.713M |
| September 17, 2026 | -1.522M |
| September 16, 2026 | -1.608M |
| September 15, 2026 | -1.664M |
| September 14, 2026 | -1.613M |
| September 11, 2026 | -1.708M |
| September 10, 2026 | -1.593M |
| September 09, 2026 | -1.540M |
| September 08, 2026 | -1.508M |
| September 04, 2026 | -1.563M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Candel Therapeutics, Inc. | 333.02M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.603M |
| Total Expenses (Quarterly) | 2.603M |
| EPS Diluted (Quarterly) | -0.577 |
| Earnings Yield | -1.09K% |
| Normalized Earnings Yield | -1092.09 |